Trinity Biotech (TRIB) Non-Current Deferred Tax Liability (2009 - 2025)

Trinity Biotech has reported Non-Current Deferred Tax Liability for 17 years, with the latest figure at $177.1 million in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability rose 27.93% year-over-year to $177.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $177.1 million (up 27.93% YoY) and the FY2025 annual result came in at $177.1 million, up 27.93% from the prior year.
• Non-Current Deferred Tax Liability climbed to $177.1 million in Q4 2025 per TRIB's latest filing, from $4.6 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $177.1 million in Q4 2025 and troughed at $195000.0 in Q4 2023.
• A 5-year average of $21.0 million and a median of $4.7 million in 2021 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability sank 96.14% in 2023, then jumped 70910.77% in 2024.
• Over 5 years, Non-Current Deferred Tax Liability stood at $4.9 million in 2021, then gained by 4.12% to $5.1 million in 2022, then tumbled by 96.14% to $195000.0 in 2023, then surged by 70910.77% to $138.5 million in 2024, then gained by 27.93% to $177.1 million in 2025.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $177.1 million, $4.6 million, and $138.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.